Critically evaluate early versus late initiation of Renal Replacement Therapy (RRT) in the critically ill patient.
Not available.
Rationale:
Advantages of early RRT:
Disadvantages of early RRT:
Evidence:
Own practice:
Vaara, Suvi T., et al. "Timing of RRT based on the presence of conventional indications." Clinical Journal of the American Society of Nephrology 9.9 (2014): 1577-1585.
Wierstra, Benjamin T., et al. "The impact of “early” versus “late” initiation of renal replacement therapy in critical care patients with acute kidney injury: a systematic review and evidence synthesis." Critical Care 20.1 (2016): 1.
Gaudry, Stéphane, et al. "Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit." New England Journal of Medicine (2016).
Seabra, Victor F., et al. "Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis." American Journal of Kidney Diseases 52.2 (2008): 272-284.
Kleinknecht, Dieter, et al. "Uremic and non-uremic complications in acute renal failure: Evaluation of early and frequent dialysis on prognosis." Kidney international 1.3 (1972): 190-196.
Egal, Mohamud, et al. "Targeting Oliguria Reversal in Goal-Directed Hemodynamic Management Does Not Reduce Renal Dysfunction in Perioperative and Critically Ill Patients: A Systematic Review and Meta-Analysis." Anesthesia & Analgesia 122.1 (2016): 173-185.
Ahmed, U. S., H. I. Iqbal, and S. R. Akbar. "Furosemide in Acute Kidney Injury–A Vexed Issue." Austin J Nephrol Hypertens 1.5 (2014): 1026.
Zarbock, Alexander, et al. "Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial." JAMA 315.20 (2016): 2190-2199.
STARRT-AKI Investigators. "Timing of initiation of renal-replacement therapy in acute kidney injury." New England Journal of Medicine (2020); 383:240-251
Gaudry, Stéphane, et al. "Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial." The Lancet 397.10281 (2021): 1293-1300.